K102474

MAR - 4 2011

510(k) Summary

1. Submitter

DRTECH Corporation

333-1 Sangdaewon1-Dong, Seongnam City

Gyeonggi-do, Korea (462-807)

www.drtech.co.kr

2. Contact Person

Beom-Jin Moon
Vice President
bimoon@drech.co.kr
+ 82-31-788-7653

3. Date Prepared

June 25, 2010

4. Device Name

FLAATZ 750E

5. Reason for Submission

New Device

6. Classification

21 CFR §892.1650

7. Product Code

KPR

8. Predicate Device

FLAATZ 750

DRTECH Corporation 510(k) No.: K080064

9. Device Description

The FLAATZ 750E is a radiographic image acquisition device. It is a fully integrated image capture and routing system under human operator control. This system may be usable by a technician in a typical radiology environment.

The FLAATZ 750E system includes a Detector Panel, Control Box, Switch Box, interconnecting Cables, and API. The Detector Panel is a direct conversion device in the form of a square plate in which the input x-ray photons are absorbed in an a-Se layer. The Control Box functions as a buffer between the Detector Panel and Operating PC white also supplying power to the Detector Panel. The Switch Box transfers signals between the Control Box and X-ray Generator and also indicates the status of the panel using LED lights. Finally, the API contains functions for image data capture and correction of defects on the image data.

DRTECH

CONFIDENTIAL

Premarket Notification: FLAATZ 750

10. Intended Use

The FLAATZ 750E is indicated for use in generating radiographic images of human anatomy. It is intended to replace radiographic film/screen systems in all general-purpose diagnostic procedures (excluding fluoroscopic, angiographic, and mammographic applications).

11. Functional and Safety Testing

The FLAATZ 750E has been evaluated as per FDA's "Guidance for the Submission of 510(k)s for Solld State X-ray Imaging Devices" and has shown good performance, substantially equivalent to the predicate device.

The FLAATZ 750E has also met applicable Electro Magnetic Compatibility (EMC) requirements.

12. Conclusion

The FLAATZ 750E is substantially equivalent to the Predicate Device in design and performance.

DRTECH

CONFIDENTIAL

Premarket Notification: FLAATZ 750



Public Health Service

Food and Drug Administration 10903 New Hampshire Avenue Document Control Room – WO66-G609 Silver Spring, MD 20993-0002

DRTECH Corporation % Mr. Charlie Mack Principal Engineer IRC 77325 Joyce Way ECHO OR 97826

Re: K102474

Trade/Device Name: FLAATZ 750E Regulation Number: 21 CFR 892.1680

Regulation Name: Stationary x-ray system

Regulatory Class: II Product Code: MQB Dated: February 18, 2011 Received: February 25, 2011 AUG 23 2013

Dear Mr. Mack:

This letter corrects our substantially equivalent letter of March 4, 2011.

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of

medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of *In Vitro* Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely Yours,

Janine M. Morr Acting Director

Division of Radiological Devices
Office of In Vitro Diagnostic Device

Evaluation and Safety

Center for Devices and Radiological Health

Enclosure

Indications for Use Statement

510(k) Number (if known):

Device Name: FLAATZ 750E

•
ndications for Use:
The FLAATZ 750E is indicated for use in generating radiographic images of human anatomy. It is intended to replace radiographic film/screen systems in all general purpose diagnostic procedures (excluding fluoroscopic, angiographic, and mammographic applications).
•
Prescription Use X AND/OR Over-The-Counter Use (21 CFR 801 Subpart C)
PLEASE DO, NO,T WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
$\sim \sim $

(Division Sign-Off)
Division of Radiological Devices
Office of In Vitro Diagnostic Device Evaluation and Safety

CONFIDENTIAL

DRTECH

Premarket Notification: FLAATZ 750E